‘Unlist us’ Amarantus asks Berlin-Bremen stock exchange
This article was originally published in Scrip
Executive Summary
Sunnyvale, California-based Amarantus BioSciences, a biotech company developing treatments and diagnostics for Parkinson's disease and traumatic brain injury, has initiated legal action to get itself removed from the Berlin-Bremen Stock Exchange (BBSE), on which it is being traded without consent.